Dr. Fujita is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
125 Paterson Street
MEB 2nd Floor
New Brunswick, NJ 08901Phone+1 908-685-3732Fax+1 732-235-7001- Is this information wrong?
Education & Training
- New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 2005 - 2008
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
- Harvard Medical SchoolClass of 2000
Certifications & Licensure
- NJ State Medical License 2005 - 2025
- NY State Medical License 2004 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 9 citationsNight vision restored in days after decades of congenital blindness.Samuel G Jacobson, Artur V Cideciyan, Allen C Ho, Alejandro J Roman, Vivian Wu, Alexandra V Garafalo, Alexander Sumaroka, Arun K Krishnan, Malgorzata Swider, Abraham A...> ;Iscience. 2022 Oct 21
- 33 citationsPost-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extensionRenato Mantegazza, Gil I. Wolfe, Srikanth Muppidi, Heinz Wiendl, Kenji P. Fujita, Fanny O'Brien, Heather D.E. Booth, James F. Howard> ;Neurology. 2021 Jan 26
- 14 citationsResponse to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard Nowak, Heinz Wiendl, Kenji P. Fujita, Fanny O'Brien, James F. Howard> ;Therapeutic Advances in Neurological Disorders. 2020 May 6
- Join now to see all
Press Mentions
- Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)April 25th, 2023
- Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society MeetingFebruary 8th, 2023
- Foundation Launching Its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated GenesNovember 10th, 2022
- Join now to see all
Hospital Affiliations
- Robert Wood Johnson University HospitalNew Brunswick, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: